MRNA - These Analysts Cut Their Forecasts On Moderna After Q3 Results | Benzinga
Moderna Inc (NASDAQ: MRNA) posted a loss for the third quarter on Thursday.
Moderna reported a quarterly loss of $(9.53), down from EPS income of $2.53. The analysts' estimate stood at $(1.93). The company's sales reached $1.8 billion (all from COVID-19 vaccine), beating the consensus of $1.4 billion and down from $3.4 billion a year ago.
Moderna shares gained 9.1% ...